Affordable Access

deepdyve-link
Publisher Website

Baricitinib counteracts metaflammation, thus protecting against diet-induced metabolic abnormalities in mice

Authors
  • Collotta, Debora1
  • Hull, William2
  • Mastrocola, Raffaella3
  • Chiazza, Fausto1
  • Cento, Alessia Sofia3
  • Murphy, Catherine2
  • Verta, Roberta1
  • Alves, Gustavo Ferreira1
  • Gaudioso, Giulia4
  • Fava, Francesca4
  • Yaqoob, Magdi2
  • Aragno, Manuela3
  • Tuohy, Kieran4
  • Thiemermann, Christoph2
  • Collino, Massimo1
  • 1 Department of Drug Science and Technology, University of Turin, Turin, Italy
  • 2 Queen Mary University of London, Center for Translational Medicine and Therapeutics, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, London, UK
  • 3 Department of Clinical and Biological Sciences, University of Turin, Turin, Italy
  • 4 Edmund Mach Foundation, San Michele all'Adige, Italy
Type
Published Article
Journal
Molecular Metabolism
Publisher
Elsevier BV
Publication Date
May 13, 2020
Volume
39
Identifiers
DOI: 10.1016/j.molmet.2020.101009
PMID: 32413585
PMCID: PMC7267733
Source
PubMed Central
Keywords
License
Unknown

Abstract

• The Jak/Stat signaling pathway is dysregulated in metabolic diseases. • The Jak2 inhibitor baricitinib exerts multi-organ protection against diet-induced metabolic derangements. • Targeting the chronic metabolic inflammation (termed metaflammation) represents an effective strategy for metabolic diseases.

Report this publication

Statistics

Seen <100 times